Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide.

Andrew D Trunk, Sagar S Patel, Josef T Prchal, Douglas W Sborov, Axel R Zander, Catherine J Lee

Abstract read

In one paragraph

Article in Leukemia research reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrew D TrunkTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Sagar S PatelTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Josef T PrchalTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Douglas W SborovTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Axel R ZanderTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Catherine J LeeTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic stem cell transplant can have high morbidity and mortality in patients with myelofibrosis (MF) and multiple myeloma (MM). This phase 2 study used a novel myeloablative regimen of split-dose busulfan, fludarabine, and then post-transplant cyclophosphamide. Four patients with MF and 2 with MM were enrolled. At 1 year, non-relapse mortality was 33.3%, and overall survival was 50%. Incidence of acute and chronic GVHD was 33.3% and 16.7%, respectively. Those surviving beyond 1 year (MF = 1, MM = 2) had durable remissions with a median follow-up of 42 months. This small study demonstrates relative safety & favorable key outcomes using this novel approach.

Indexed as

Allogeneic transplantConditioningMultiple myelomaMyelofibrosisPreparative

Identifiers

PMID37701906

DOI10.1016/j.lrr.2023.100388

PMCPMC10493243

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.